# Burden of Vitiligo in Canada: Retrospective Analysis of a Canadian Public Claims Database

## TL;DR

This study analyzed the healthcare burden of vitiligo in Québec, Canada, finding higher healthcare use and costs among patients compared to controls.

## Contribution

The study provides new insights into the healthcare resource utilization and costs associated with vitiligo in a Canadian population.

## Key findings

- Patients with vitiligo had significantly higher outpatient visits and costs compared to controls.
- Vitiligo patients had increased total healthcare costs in the year following diagnosis.
- Treatment patterns for vitiligo were highly variable, with many different sequences reported.

## Abstract

Vitiligo is an autoimmune disease resulting in skin depigmentation. Treatment options are limited.

To examine disease burden and healthcare resource utilization (HCRU) among patients with vitiligo in Québec, Canada.

In this retrospective study, data were obtained from the Régie de l’Assurance Maladie du Québec (RAMQ) databases for 125,000 random individuals from January 2010 to December 2019. The International Classification of Diseases, Ninth Revision (ICD-9) diagnostic code [709.x (other skin disorders)] with vitiligo-related treatment was used to identify patients with vitiligo. Patient characteristics and treatments, including treatment type, episodes (treatments used without discontinuation), and sequences (treatment episodes ≥30 days), were assessed. Annualized HCRU and costs (2021 adjusted) included all-cause hospitalization, emergency department visits, outpatient visits, and medications among patients with vitiligo (n = 113) and age- and sex-matched non-vitiligo controls (n = 339).

Of patients with vitiligo (mean age, 50.0 years; 68.1% female) identified using ICD-9 code 709.x with vitiligo-related treatment, 36.3% received ≥4 treatment episodes. Treatment patterns were heterogeneous, with 43 different sequences reported. Annualized mean outpatient visits (16.1 vs 5.5) and all-cause outpatient service costs per patient were significantly higher in the vitiligo versus the control group (CAN$1037 vs CAN$523; P < .01). Total all-cause services costs were higher for patients with vitiligo in the year after versus before diagnosis (CAN$3679 vs CAN$2085; P = .04).

Vitiligo is associated with significant burden and HCRU among patients in Québec, Canada, who were identified by ICD-9 code 709.x plus vitiligo-related treatment. Measurement of true vitiligo burden remains challenging.